Health Care • Misc Health and Biotechnology Services
$1.14 ▼ -0.06
(-5.00%)
MKT CAP: $11.3M • VOL: 284.4K
52W L $1 52W H $20,909
NIVF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.7M | $5.4M | $5.1M |
| YoY Revenue Growth % | -13.0% | +5.8% | — |
| Gross Profit | $955.8K | $1.8M | — |
| Gross Margin % | 20.2% | 33.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$10.7M | -$1.2M | $42.2K |
| Operating Margin % | -80.0% | -21.4% | 0.8% |
| Net Income (GAAP) | $9.9M | -$524.6K | $130.2K |
| EBITDA (Normalized) | -$10.6M | -$1.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.9M | -$8.3M | -$1.8M |
| Capital Expenditures (CapEx) | $135.0K | $53.0K | — |
| Free Cash Flow (FCF) | -$11.1M | -$8.3M | -$1.8M |
| FCF Margin % | -80.0% | -80.0% | -34.4% |
| Return on Invested Capital (ROIC %) | -32.8% | -45.0% | — |
| Cash & Short-Term Equivalents | $758.6K | $457.7K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $26.6M | -$1.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NIVF.